{"code":"Z17.31","type":"code","title":"Human epidermal growth factor receptor 2 positive status","codeAlso":[],"includes":[],"modern_v":"official26","codeFirst":["malignant neoplasm, such as:","malignant neoplasm of breast (C50.-)","malignant neoplasm of ovary (C56.-)"],"excludes1":[],"excludes2":[],"isBillable":true,"fyEffectivity":{"fy2026":true,"fy2027":true,"billableFy2026":true,"billableFy2027":true},"sibling_codes":["Z17","Z17.0","Z17.1","Z17.2","Z17.21","Z17.22","Z17.3","Z17.32","Z17.4","Z17.41","Z17.410","Z17.411","Z17.42","Z17.420","Z17.421"],"inclusionTerms":["HER2+"],"sibling_titles":{"code":"Z17.421","title":"Hormone receptor negative with human epidermal growth factor receptor 2 negative status","isBillable":true},"useAdditionalCode":[],"clinicalDefinition":"Human epidermal growth factor receptor 2 positive status is a billable ICD-10-CM diagnosis code (Z17.31). Inclusion terms: HER2+. Code first: malignant neoplasm, such as:; malignant neoplasm of breast (C50.-); malignant neoplasm of ovary (C56.-).","officialDefinition":"Human epidermal growth factor receptor 2 positive status is a billable ICD-10-CM diagnosis code (Z17.31). Inclusion terms: HER2+. Code first: malignant neoplasm, such as:; malignant neoplasm of breast (C50.-); malignant neoplasm of ovary (C56.-).","seventhCharacterInstructions":[],"workflowProtocols":[],"guidelines":{"whenToUse":[],"whenNotToUse":[],"commonBillingMistakes":[],"codeComparisons":[],"documentationChecklist":[]},"domainLandscape":{"summary":"Primary diagnostic domain and clinical landscape evaluation.","keyCategories":[],"diagnosticContinuum":"Progression continuum from acute presentation to resolution."},"children":[],"hierarchy":[],"relatedCodes":[],"relevantCPTCodes":[],"documentationTips":[],"caseStudies":[],"description":"","overview":""}